evaluation of the effects of a biostimulator and dermal fillers for cheek augmentation and contour deficiencies

Conditions: Photoaging; Weight Loss; Skin Laxity; Photodamaged Skin; Volume Deficiency of the Midface

Summary: adult subjects with a history of or currently taking glucagon-like peptide-1 (glp-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with sculptra correction of fine lines and wrinkles in the cheek area and restylane lyft or restylane contour for cheek augmentation and correction of midface contour deficiencies.

this is a multi-center, open-label study. subjects will be screened on the basis of the selection criteria for study qualification. eligible subjects will have initial treatment of sculptra and restylane lyft or restylane contour on both cheeks at the baseline visit. at week 4, subjects will receive a second sculptra treatment on both cheeks for optimal correction and an optional touch-up of restylane lyft or restylane contour for optimal correction, defined as at least a 1-grade improvement on the gcws and mmvs. at week 8, subjects will receive an optional sculptra treatment on both cheeks for optimal correction. subjects will have follow-up visits at week 16, week 28, and week 40 if the last sculptra treatment is at week 4 or at week 20, week 32, and week 44 if the last sculptra treatment is at week 8.

Eligibility criteria:
inclusion criteria: * any fitzpatrick skin types i-vi, with effort to include minimum n = 1 for each category per site * any races and ethnicities, with effort to include minimum n = 2 per site for whom identify as american indian or alaska native, eastern/southeastern asian, south asians, hispanic or latino, black or african american, native hawaiian or other pacific islander, etc. * subject with moderate-to-severe cheek wrinkles on the gcws * subject with mild-to-severe midface contour deficiencies on the mmvs * subject with intent to undergo correction of cheek augmentation or midface contour deficiencies. * subject with history of taking or currently taking glp-1 receptor agonist medications such as semaglutide, liraglutide, etc. * subject with stable body mass index (bmi) within 4-6 weeks before study start. * subject willing to maintain a stable body mass index (bmi, ± 2 kg/m2) throughout the study. * willing to maintain the current lifestyle and daily routine (e.g., diet, exercise, sleep, etc.) throughout the study. * subject willing to be photographed at each visit. * subject willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study. * for female subjects of childbearing potential, she agrees to use an acceptable form of effective birth control for the duration of the study. subjects must be willing to take a urine pregnancy test (upt) prior to all treatments. (females of non-childbearing potential, e.g., post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy, or bilateral ovariectomy, are not required to have a upt.) * male subjects must be willing to shave prior to each study visit. * ability to read, understand and give consent for participation in the study. * agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments. exclusion criteria: * pregnant, breastfeeding, or planning pregnancy during the course of the study. * current smokers or consumer of nicotine. * history of allergy or hypersensitivity to any ingredient of the treatment products, anesthetics or lidocaine * previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions * previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except the lips * history of injectable polymethylmethacrylate (pmma) treatment * previous treatment/procedure in the face in the previous 6 months that, in the investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures in the treatment area at any time during the study * presence of any disease or lesions near or on the area to be treated * history of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation (e.g., aspirin or other non-steroidal anti-inflammatory drugs), omega 3, or vitamin e within 14 days before treatment. omega 3 and vitamin e are acceptable only as part of a standard multivitamin formulation. * previous surgery, including plastic surgery, lifting threads, tissue grafting, or tissue augmentation with permanent implants, silicone, tattoo affecting the treatment area, or any procedure, at the discretion of the investigator, would interfere with the outcome of the study. * any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion * other condition preventing the subject from entering the study in the investigator's opinion * study site personnel, close relatives of the study site personnel (e.g., parents, children, siblings, or spouse), or employees and close relatives of employees at the sponsor company. * participation in any interventional clinical study within 30 days of screening.